Samyang

Samyang Holdings, through its Biopharm Division, is a prominent South Korean healthcare company specializing in oncology, medical devices, and advanced drug delivery systems. The company is globally recognized for its proprietary SENS (Samyang's Enhanced Nano-delivery System) platform, which utilizes polymeric micelle technology to improve the solubility and delivery of hydrophobic drugs. Its flagship product, Genexol-PM, is a cremophor-free formulation of paclitaxel that has become a standard of care in South Korea for treating breast, lung, and ovarian cancers. Beyond oncology, Samyang is a world leader in the production of biodegradable surgical sutures, supplying raw materials and finished products to major global medical device firms. The company is actively expanding its R&D efforts into next-generation modalities, including mRNA-based therapeutics and gene delivery systems using its specialized lipid and polymer technologies. With a strong manufacturing base in South Korea and an innovation hub in the United States, Samyang continues to advance its clinical pipeline and global commercial footprint.